Back to Search
Start Over
Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.
- Source :
- Medical Oncology; May2018, Vol. 35 Issue 5, p1-1, 1p
- Publication Year :
- 2018
-
Abstract
- To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan-Meier (log-rank test) approach. Fifty-five patients were treated on 77 bone oligometastases. Median age, initial PSA and pre-SBRT PSA were 72 years, 9.12 and 3.5 ng/mL, respectively. Twenty-five patients (45%) received SBRT alone while the remaining 30 patients (55%) received concomitant ADT. Median follow-up was 24.6 months (range 3.0-67.2 months). No acute or late toxicity of grade > 1 was reported. Clinical progression was observed in 38 (69%) patients. 1-year biochemical progression-free survival (b-PFS), clinical progression-free survival (c-PFS), prostate-specific survival (PCSS) and local control (LC) rates were 51, 56, 100 and 83%, respectively. Comparing patients treated with SBRT alone and with concomitant ADT, no significant differences were found for those outcomes. SBRT is safe and allows high 1-year LC rate (83%) with low toxicity profile. No significant improvement in outcomes was registered with the addition of ADT to SBRT. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13570560
- Volume :
- 35
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Medical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 129594207
- Full Text :
- https://doi.org/10.1007/s12032-018-1137-0